Why the study?
Does subcutaneous low-molecular-weight heparin improve safety and efficacy compared to intravenous unfractionated heparin in patients with acute deep-vein thrombosis?
Does subcutaneous low-molecular-weight heparin improve safety and efficacy compared to intravenous unfractionated heparin in patients with acute deep-vein thrombosis?
Answers are grounded in this paper and cite their sources.
Subcutaneous low-molecular-weight heparin appears to be as safe and effective as continuous intravenous unfractionated heparin for achieving reperfusion in acute deep-vein thrombosis.
Fifty patients presenting with acute deep-vein thrombosis were randomized in a prospective, controlled study to determine the safety and efficacy of a treatment with low-molecular-weight (LMW) heparin compared with unfractionated heparin. LMW heparin (n = 24) was administered twice daily subcutaneously at a dose of 2 X 150 anti-Xa units/kg body weight, and unfractionated heparin (n = 26) was given intravenously by continuous infusion at a dose of 450 anti-Xa units/kg body weight daily for 10 days. Doses were adjusted to maintain peak anti-Xa levels between 0.5 and 1.0 anti-Xa units per milliliter. One patient in the unfractionated heparin group and 2 patients in the LMW heparin group suffered from bleeding complications. Two patients on LMW heparin and on unfractionated heparin had high evidence of pulmonary embolism based on defects on ventilation-perfusion scintigraphy. Control phlebography and duplex sonography demonstrated a significant improvement during both treatment regimens. Reperfusion of the deep-vein system was 70% with LMW heparin and 75% with unfractionated heparin. The anti-Xa levels were significantly higher in the LMW heparin group, and activated partial thromboplastin and thrombin clotting times were significantly higher in the group receiving unfractionated heparin. Thrombin-antithrombin III complexes and D-dimer concentration decreased during the treatment, but did not differ between the two regimens. At the end of the treatment period with LMW heparin, protein C and antithrombin III were significantly higher.
No takes yet. Share an insight, caveat, or question.
Harenberg et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: